Welcome to EXIR PHARMACEUTICAL CO. WebSite

» MODIFY YOUR SEARCH

 
» NEWS AND EVENTS

The gathering was held from 24th August 2008 till 26th August in Tehran...

Welcome to EXIR PHARMACEUTICAL CO. WebSite
» ARTICLE OF THE DAY

Comparison of two treatment regimens in symptomaticaliy homogenous gerd patient Populations : pantoprazole relieves gastrointestinal symptoms significantily better than omeprazole

Welcome to EXIR PHARMACEUTICAL CO. WebSite

Welcome to EXIR PHARMACEUTICAL CO. WebSite
 Â» EXIR PRODUCTS  
 
 
Atorvastatin - Exir
  Generic Name:
  Atorvastatin
  Dosage:
  20 mg F.C.Tab /30 s

--- 

 

 
Atorvastatin - Exir
  Generic Name:
  Atorvastatin
  Dosage:
  40 mg F.C.Tab /30 s

--- 

 

 
 
Captopril - Exir
  Generic Name:
  Captopril
  Dosage:
  25 mg Tab/100 s

Capotril® is a selective inhibitor of angiotensin converting enzyme (ACE) and was the first ACE inhibitor to be used clinically. ACE is a peptidyl carboxypeptidase that catalyzes the conversion of angiotensin I to the active octapeptide angiotensin II in blood and other tissues. Angiotensin II increases blood pressure through its direct vaso-constrictor effect and, indirectly, through stimulation of aldosterone secretion and the sympathetic nervous system. ACE inhibition results in reduced plasma angiotensin II and as a result of the loss of feedback inhibition, plasma renin activity increases. 

 

 
Captopril - Exir
  Generic Name:
  Captopril
  Dosage:
  50 mg Tab/100 s

Capotril® is a selective inhibitor of angiotensin converting enzyme (ACE) and was the first ACE inhibitor to be used clinically. ACE is a peptidyl carboxypeptidase that catalyzes the conversion of angiotensin I to the active octapeptide angiotensin II in blood and other tissues. Angiotensin II increases blood pressure through its direct vaso-constrictor effect and, indirectly, through stimulation of aldosterone secretion and the sympathetic nervous system. ACE inhibition results in reduced plasma angiotensin II and as a result of the loss of feedback inhibition, plasma renin activity increases. 

 

 

   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25   

 

Copyright© 2005 EXIR PHARMACEUTICAL CO. All rights reserved.